Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Actinium is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

TypePublic
HQNew York, US
Founded2000
Size (employees)25 (est)+9%
Websiteactiniumpharma.com
Actinium Pharmaceuticals was founded in 2000 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Actinium Pharmaceuticals

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board
Mark Berger

Mark Berger

Chief Medical Officer
Dale L. Ludwig

Dale L. Ludwig

Chief Scientific Officer
Anil Kapur

Anil Kapur

Chief Commercial Officer
David Gould

David Gould

Senior Vice President, Corporate Development and Affairs
Vijay Reddy

Vijay Reddy

Vice President, Clinical Development
Show more

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, (HQ)
275 Madison Ave
Show all (1)
Report incorrect company information

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Revenue

USD

Net income (Q3, 2018)

(6.1m)

EBIT (Q3, 2018)

(6.2m)

Market capitalization (4-Dec-2018)

60.2m

Closing stock price (4-Dec-2018)

0.5

Cash (30-Sep-2018)

14.8m
Actinium Pharmaceuticals's current market capitalization is $60.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

3.9m10.2m11.5m9.3m9.2m

R&D expense

12.3m

Operating expense total

6.6m22.4m24.8m26.8m26.9m

EBIT

(6.6m)(22.5m)(24.8m)(26.8m)(26.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

830.7k1.7m2.4m3.3m3.8m3.6m1.8m2.2m2.8m1.4m3.3m2.8m1.7m1.9m1.6m2.0m

R&D expense

4.5m

Operating expense total

1.6m4.1m4.4m7.0m7.9m7.4m4.6m6.0m6.9m7.1m7.8m7.2m6.7m6.4m4.9m6.2m

Depreciation and amortization

1.4k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.5m6.7m25.6m20.5m17.4m

Accounts Receivable

2.1b

Inventories

218.4k699.9k803.5k1.8m

Current Assets

5.8m7.4m26.5m22.4m17.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(10.8m)(24.7m)(21.0m)(24.3m)(26.6m)

Depreciation and Amortization

1.6k37.9k53.5k77.5k55.9k

Inventories

106.6k(193.9k)162.1k(1.0m)

Accounts Payable

(518.1k)(793.9k)2.7m405.2k
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Actinium Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Actinium Pharmaceuticals News and Updates

Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that the next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program, after successful completion of the Actimab-A phase 2 trial in Acute...

Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will host a conference call and webinar today at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 –...

Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program...
Report incorrect company information

Actinium Pharmaceuticals Blogs

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

- Key highlights include near universal engraftment and no 100-day non-relapse mortality in patients randomized to Iomab-B arm; 79% of patients in the control arm failed to achieve a complete response necessary for conventional bone marrow transplant - 67% (10/15) of patients eligible for…

Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate

- Phase 2 trial successfully reached predetermined response criteria in difficult to treat over 60, unfit patient population and demonstrated minimal extramedullary toxicities - Actinium's CD33 program development to bifurcate as announced recently with high doses of the ARC or Antibody Radiation C…

Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

- Actinium presentation scheduled for November 27 at 2:10pm EST NEW YORK, Nov. 19, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) announced today that management will present at the 30th Annual Piper Jaffray Healthcare conference that is being held at the Lotte New Yo…

Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference

- Presentation at 9:00 AM CET on Tuesday, November 6, 2018 - Actinium to highlight its highly differentiated targeted conditioning Antibody Radiation Conjugates including Pivotal Phase 3 Program Iomab-B, CD33 Actimab program including Actimab-MDS, Antibody Warhead Enabling technology platform and th…

Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data

- All patients receiving Iomab-B therapy in both the study arm and those that crossed over from the control arm achieved engraftment following bone marrow transplant despite high bone marrow blast counts - 88% of patients in the control arm failed to achieve a complete response with 65% …

Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference

-Actinium executives will showcase multiple partnering opportunities available via pipeline candidates and technology platform -Assets available for partnering include highly differentiated targeted conditioning Antibody Radio-Conjugates including Pivotal Phase 3 Program Iomab-B, CD33 Actimab progra…
Show more

Actinium Pharmaceuticals Company Life and Culture

Report incorrect company information

Actinium Pharmaceuticals Frequently Asked Questions

  • When was Actinium Pharmaceuticals founded?

    Actinium Pharmaceuticals was founded in 2000.

  • Who are Actinium Pharmaceuticals key executives?

    Actinium Pharmaceuticals's key executives are Sandesh Seth, Mark Berger and Dale L. Ludwig.

  • How many employees does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 25 employees.

  • Who are Actinium Pharmaceuticals competitors?

    Competitors of Actinium Pharmaceuticals include Interpace Diagnostics, Adaptive Biotechnologies and Cambridge Epigenetix.

  • Where is Actinium Pharmaceuticals headquarters?

    Actinium Pharmaceuticals headquarters is located at 275 Madison Ave, New York.

  • Where are Actinium Pharmaceuticals offices?

    Actinium Pharmaceuticals has an office in New York.

  • How many offices does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 1 office.